Barclays PLC Rezolute, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Rezolute, Inc. stock. As of the latest transaction made, Barclays PLC holds 309,696 shares of RZLT stock, worth $3.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
309,696
Previous 398,535
22.29%
Holding current value
$3.07 Million
Previous $1.78 Million
61.9%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RZLT
# of Institutions
124Shares Held
68.9MCall Options Held
1.01MPut Options Held
57.2K-
Federated Hermes, Inc. Pittsburgh, PA14MShares$139 Million0.25% of portfolio
-
Siren, L.L.C. New York, NY4.87MShares$48.3 Million1.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.41MShares$43.7 Million0.0% of portfolio
-
Blackstone Inc New York, NY3.02MShares$30 Million0.13% of portfolio
-
Mangrove Partners New York, NY2.88MShares$28.6 Million3.44% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $385M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...